Jupiter Endovascular
Jupiter Endovascular is a medical technology startup dedicated to transforming endovascular therapy through innovative procedures and platforms like Endoportal Control™. Their mission is to develop advanced catheter-based interventions that bring the precision and control of direct surgical access to minimally invasive treatments, with a focus on conditions such as pulmonary embolism. The company aims to reimagine therapies for millions of patients worldwide by enabling safer, more effective, and more accessible endovascular procedures.
Industries
Nr. of Employees
small (1-50)
Jupiter Endovascular
155 Jefferson Dr, Suite 100, Menlo Park, CA 94025
Products
Pulmonary embolectomy system with deployable intravascular stabilization
A catheter-based pulmonary embolectomy system that incorporates a deployable intravascular stabilization mechanism delivered over a guidewire, designed to be pressurized in situ to create a stable base for therapeutic device delivery and thrombus removal.
Pulmonary embolectomy system with deployable intravascular stabilization
A catheter-based pulmonary embolectomy system that incorporates a deployable intravascular stabilization mechanism delivered over a guidewire, designed to be pressurized in situ to create a stable base for therapeutic device delivery and thrombus removal.
Services
Sponsorship and operational execution of prospective, single-arm, multicenter clinical trials to evaluate safety and clinical outcomes of catheter-based interventional systems.
Conduct and management of animal studies to evaluate device navigation, stability, and procedural performance prior to human studies.
Sponsorship and operational execution of prospective, single-arm, multicenter clinical trials to evaluate safety and clinical outcomes of catheter-based interventional systems.
Conduct and management of animal studies to evaluate device navigation, stability, and procedural performance prior to human studies.
Expertise Areas
- Endovascular device development
- Percutaneous pulmonary embolectomy
- Clinical trial management for device studies
- Preclinical animal-model testing
Key Technologies
- Deployable intravascular anchoring/fixation via pressurization
- Guidewire-delivered flexible catheter systems
- Large-bore aspiration catheter integration
- Percutaneous embolectomy techniques
News & Updates
Jupiter Endovascular announced its exit from stealth mode with a $21 million financing round to support pivotal trials for pulmonary embolism treatment using Endoportal Control™ technology.
The first two patients were treated in a multicenter study at St. John Paul II Hospital in Krakow, Poland, demonstrating the safety and effectiveness of the Vertex system with Endoportal Control™ technology.
The first U.S. case was performed at Staten Island University Hospital, marking the beginning of the SPIRARE II pivotal trial to evaluate the Vertex Pulmonary Embolectomy System.
Jupiter Endovascular received FDA approval for its SPIRARE II pivotal trial, which will study the Vertex system for treating acute pulmonary embolism.
Jupiter Endovascular announced its exit from stealth mode with a $21 million financing round to support pivotal trials for pulmonary embolism treatment using Endoportal Control™ technology.
The first two patients were treated in a multicenter study at St. John Paul II Hospital in Krakow, Poland, demonstrating the safety and effectiveness of the Vertex system with Endoportal Control™ technology.
The first U.S. case was performed at Staten Island University Hospital, marking the beginning of the SPIRARE II pivotal trial to evaluate the Vertex Pulmonary Embolectomy System.
Jupiter Endovascular received FDA approval for its SPIRARE II pivotal trial, which will study the Vertex system for treating acute pulmonary embolism.